论文部分内容阅读
目的:观察康艾注射液联合化疗治疗晚期非小细胞肺癌患者临床疗效及安全性,探讨相关护理体会。方法:138例晚期非小细胞肺癌患者按照随机抽签法分为对照组与治疗组,各69例。对照组采用艾迪注射液治疗;观察组采用艾迪注射液联合康艾注射液治疗;两组患者均实施相关护理。观察两组患者临床疗效和生存质量及不良反应。结果:治疗后,治疗组治疗获益率为55.07%(38/69)明显高于对照组44.93%(31/69)(P<0.05);两组患者KPS改善率比较(P<0.05)。治疗组不良反应率明显低于对照组(P<0.05)。结论:临床应用康艾注射液联合化疗治疗晚期非小细胞肺癌患者,虽其与单纯药物化疗治疗效果相当,但其可提高患者临床整体治疗效果,且产生不良反应较少。治疗期间实施相关护理干预,可有效改善患者生存质量。
Objective: To observe the clinical efficacy and safety of Kangai injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer and to explore the related nursing experience. Methods: One hundred and thirty-eight patients with advanced non-small cell lung cancer were randomly divided into control group and treatment group according to random sampling method, with 69 cases in each. The control group was treated with Aidi Injection. The observation group was treated with Aidi Injection combined with Kangai Injection. The patients in both groups were given nursing care. The clinical efficacy, quality of life and adverse reactions of the two groups were observed. Results: After treatment, the benefit rate of the treatment group was 55.07% (38/69), which was significantly higher than that of the control group (44.93%, 31/69) (P <0.05). The improvement rate of KPS between the two groups was significant (P <0.05). Adverse reaction rate in the treatment group was significantly lower than that in the control group (P <0.05). Conclusion: The clinical application of Kang Ai injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer patients, although with chemotherapy alone is quite effective, but it can improve the overall clinical treatment of patients with fewer adverse reactions. The implementation of the relevant nursing intervention during treatment can effectively improve the quality of life of patients.